Market Eyes LiveMedtronic plc (MDT) Stock Rating & Analysis
MELANY's data-driven read on Medtronic plc · Electromedical & Electrotherapeutic Apparatus.
Medtronic, among the largest medical-device companies, develops and manufactures therapeutic devices for chronic diseases, including pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. It markets mainly to healthcare institutions and physicians in the US, Western Europe, and Japan, with foreign sales making up roughly 50% of total sales.
Why MDT scores 67/100
MELANY scores Medtronic plc 67/100 by weighing eight factors. Here is how MDT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 14.4x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 65%
Direction and relative strength of the recent share-price trend.
- Price +9.8% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Earnings in 12 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 12 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for MDT
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Medtronic plc sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds MDT's momentum and catalyst factors above.
MDT trade plan (members only)
MELANY has a full position plan for Medtronic plc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates MDT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Medtronic plc's 67/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about MDT
Is Medtronic plc (MDT) a buy?
As of 2026-08-20, MELANY rated Medtronic plc Favorable with a composite score of 67/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Medtronic plc's MELANY score?
Medtronic plc (MDT) has a MELANY composite score of 67/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the MDT stock rating calculated?
MELANY scores MDT from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Medtronic plc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Medtronic plc (MDT) Favorable with a composite of 67/100 as of 2026-08-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the MDT stock price forecast?
MELANY does not publish price targets or forecasts for MDT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 67/100 across eight factors for Medtronic plc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is MDT stock overvalued or undervalued?
MELANY's valuation factor currently reads 62/100 for Medtronic plc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MDT's read.
What price should I buy MDT at?
Rather than chasing the current price, MELANY computes a smart entry zone for MDT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying MDT stock?
The top risks MELANY currently flags for Medtronic plc: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Medtronic plc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 66/100 for Medtronic plc, and earnings track record, at 69/100. The 67/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will MDT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 51/100 for MDT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this MDT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-20. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores MDT continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
MDT's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.